GENEVA, Nov 28, 2007 (AFP) - Swiss firm Mymetics said on Wednesday it will start in 2008 Phase 1 trials of a possible anti-AIDS vaccine that seeks to produce mucosal antibodies that can resist HIV.
The trials will take place in Belgium on a sample of between 30 to 40 women, Mymetics' scientific director Sylvain Fleury told journalists.
Over 85 percent of HIV infections are the result of genital or intestinal mucosa (membrane in body passages) being exposed to the disease, he said.
Any HIV vaccine that could successfully achieve antibody production into both genital and intestinal tracts might open the door to a new HIV vaccine approach, Mymetics claimed on its website.
The Swiss-based company, which is quoted on the Nasdaq stock index in New York, said it hopes to take its research further, and then either enter into a partnership with a larger company, or sell the product technology, in order to move to Phase III trials targeted at between 15,000-20,000 people.
The cost of such trials is too much for Mymetics to afford on its own, company chairman Christian Rochet said.
Mymetics estimates the vaccine could produce annual sales revenue of between two to four billion dollars (1.3-2.7 billion euros) per year.
071128
AF071198
Copyright ©AFP 2007. All Rights Reserved. AFP articles contained on the AEGiS web site may not be reproduced, distributed, transmitted, displayed, published or broadcast without AFP's prior written permission. You may make one copy of each article for your personal, non-commercial use only; more copies would require AFP's prior written permission obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP photos or materials. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP stories, photos or graphics. http://www.afp.com/
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.